HMPV Outbreak: Diagnostics Stocks Buzz As India Reports Two Cases, Vijaya Diagnostics, Dr. Lal Path Labs Up
Shares of diagnostics companies led by Vijaya Diagnostics Ltd. and Dr. Lal Path Labs Ltd. buzzed in early trade on Monday as concerns mounted over the HMPV outbreak in China and reports of the first two cases being detected in India.
Vijaya Diagnostics and Dr. Lal Path Labs shares gained as much as 2.9% each, while Metropolis Healthcare Ltd. and Thyrocare Technologies Ltd. jumped 1.8%.
Suraksha Diagnostics Ltd. fell 2.5% and Krsnaa Diagnostics dropped 1.7%.
Indian Council of Medical Research has detected two cases of Human Metapneumovirus (HMPV) in Karnataka through routine surveillance. It said the surveillance system is robust and there is no unusual surge in influenza-like illness, or severe acute respiratory infection cases in the country.

In response to growing concerns, the Union Health Ministry assured the public that India is well-prepared to handle respiratory illnesses. It also requested updates from the World Health Organization regarding the situation in China, where multiple respiratory viruses have recently spiked.
Dr Jacob John, virologist and professor at CMC Vellore, told NDTV Profit that HMPV is far from a cause for panic and reassured the public there was no need for heightened alarm.
Meanwhile, Indian equity benchmarks saw big declines. The Nifty 50 and BSE Sensex were trading 1.2% lower at noon.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.